However, it is crucial to understand that BPC-157 is not approved for human use by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the European Medicines Agency (EMA), or the US Food and Drug Administration (FDA)
Reported or proposed issue Long-term or repeated-cycle effects Evidence source No long-term human trial Known or theoretical
BAC water sold separately

Neurological: convulsions, increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment, vertigo, headache Endocrine: menstrual irregularities, development of cushingoid state, suppression of fetal intrauterine or childhood growth, lack of secondary response of the adrenal cortex or pituitary gland, particularly in situations of stress such as trauma, surgery or illness, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements of insulin or oral hypoglycemic agents in diabetic patients Ophtalmic: posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos Metabolic: negative nitrogen balance due to protein catabolism Psychiatric: euphoria, mood swings, severe depression to frank psychotic manifestations, personality changes, hyperirritability, insomnia Others: anaphylactoid or hypertensive reactions and hypotension or shock-like reaction Cyanocobalamin and hydroxocobalamin: hypervitaminosis and side effects were not observed with their use Dosage and administration Adults Coated tablets: 1 coated tablet 2 times a day

Each vial contains lyophilized peptides manufactured under strict quality standards and independently third-party tested to help verify identity and purity